A Phase I, Single Centre, Randomised, Single Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Inhaled AZD8871 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs AZD 8871 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 01 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.